Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inactivated influenza vaccine
- Development stage
- Approved
- Lead developer
- University of Michigan
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Inactivated influenza vaccine contains killed influenza virus strains that stimulate an immune response without causing disease. The vaccine is reformulated annually to match circulating virus strains and is administered to prevent seasonal influenza. It works by triggering the immune system to produce antibodies against specific influenza virus strains included in the vaccine.
- Brand names
- FluarixFluLavalAfluriaAgrifluFluad
- Other names
- killed influenza virus vaccine
02
Targets
NeuraminidaseHA (Hemagglutinin)
Beyond the preview
Go deeper on inactivated influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inactivated influenza vaccine.